These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 10524003)

  • 1. [The use of modern economic methods for the rational choice of drugs].
    Khveshchuk PF; Rudakova AV; Galin AL
    Voen Med Zh; 1999 Aug; 320(8):54-9. PubMed ID: 10524003
    [No Abstract]   [Full Text] [Related]  

  • 2. [Helicobacter pylori eradication in ulcer patients. Quality of life improves, costs decline].
    MMW Fortschr Med; 2003 Aug; 145(33-34):55. PubMed ID: 14526577
    [No Abstract]   [Full Text] [Related]  

  • 3. The health economics of Helicobacter pylori infection.
    Moayyedi P
    Best Pract Res Clin Gastroenterol; 2007; 21(2):347-61. PubMed ID: 17382282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Helicobacter pylori-associated ulcer bleeding: should we test for eradication after treatment?
    Pohl H; Finlayson SR; Sonnenberg A; Robertson DJ
    Aliment Pharmacol Ther; 2005 Sep; 22(6):529-37. PubMed ID: 16167969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacoeconomics in the therapy of peptic ulcer].
    Tesar T; Foltán V; Huorka M
    Ceska Slov Farm; 2002 Mar; 51(2):78-83. PubMed ID: 11928281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of life measurement clarifies the cost-effectiveness of Helicobacter pylori eradication in peptic ulcer disease and uninvestigated dyspepsia.
    Groeneveld PW; Lieu TA; Fendrick AM; Hurley LB; Ackerson LM; Levin TR; Allison JE
    Am J Gastroenterol; 2001 Feb; 96(2):338-47. PubMed ID: 11232673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of Helicobacter pylori "test and treat" for patients with typical reflux symptoms in a population with a high prevalence of H. pylori infection: a Markov model analysis.
    You JH; Wong PL; Wu JC
    Scand J Gastroenterol; 2006 Jan; 41(1):21-9. PubMed ID: 16373272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Economic assessment of the use of biological medications in military medicine].
    Belevitin AB; Tyrenko VV; Grigor'eva OA; Bologov SG
    Voen Med Zh; 2010 Dec; 331(12):4-8. PubMed ID: 21488354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluations in medicine: still more questions than answers?
    Grossi E
    Ital J Gastroenterol Hepatol; 1998 Aug; 30(4):347-50. PubMed ID: 9789124
    [No Abstract]   [Full Text] [Related]  

  • 10. Using pharmaceutical cost analyses for decision making.
    U'Ren NA
    Hosp Cost Manag Account; 1997 Nov; 9(8):1-7. PubMed ID: 10178832
    [No Abstract]   [Full Text] [Related]  

  • 11. [Medical experts groups and choice of medications. A fair prioritization process guarantees the reliability of the choice of medications].
    Garpenby P
    Lakartidningen; 2004 Aug; 101(32-33):2480-2, 2484. PubMed ID: 15346621
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost-effectiveness analysis between primary and secondary preventive strategies for gastric cancer.
    Lee YC; Lin JT; Wu HM; Liu TY; Yen MF; Chiu HM; Wang HP; Wu MS; Hsiu-Hsi Chen T
    Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):875-85. PubMed ID: 17507609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of drug iatrogeny by medico-economic modelling techniques].
    Beresniak A; Taboulet F
    Therapie; 1997; 52(1):59-63. PubMed ID: 9183924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Medical-economical reasoning of volumes of financing of medicamental aid in the Armed Forces].
    Belevitin AB; Miroshnichenko IuV; Bunin SA; Goriachev AB
    Voen Med Zh; 2009 Dec; 330(12):4-9. PubMed ID: 20201362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The economics of drug discovery and the ultimate valuation of pharmacotherapies in the marketplace.
    Sollano JA; Kirsch JM; Bala MV; Chambers MG; Harpole LH
    Clin Pharmacol Ther; 2008 Aug; 84(2):263-6. PubMed ID: 18547999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The military health services system model for pharmacoeconomic decision making.
    Ries AJ; Potyk RP; Brier KL; Miller MR; Tornow JJ; Weber MP; Finder SF; Reeves CS
    Med Interface; 1995 May; 8(5):132-7. PubMed ID: 10142786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testing and Treating Helicobacter pylori Infection in Individuals With Family History of Gastric Cancer is Cost-effective.
    Rustgi SD; Oh A; Hur C
    Gastroenterology; 2021 Dec; 161(6):2051-2052.e4. PubMed ID: 34461053
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost-effectiveness data on biologics needed.
    Sheridan C; Katsnelson A
    Nat Biotechnol; 2005 Mar; 23(3):272-3. PubMed ID: 15765069
    [No Abstract]   [Full Text] [Related]  

  • 19. Eradication therapy for Helicobacter pylori.
    Vakil N; Megraud F
    Gastroenterology; 2007 Sep; 133(3):985-1001. PubMed ID: 17854602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: Markov decision analysis].
    Wang Q; Jin PH; Lin GW; Xu SR; Chen J
    Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Feb; 24(2):135-9. PubMed ID: 12697117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.